Infections from seven clinical trials of ixekizumab, an anti ‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

ConclusionsOverall, infections occurred in a higher percentage of patients treated with ixekizumab vs. placebo during the first 12 weeks of treatment; however, specific infection rates were comparable overall across treatment groups. Incidences of serious infections were low and similar across treatment groups.

Source: British Journal of Dermatology - November 16, 2017 Category: Dermatology Authors: K.A. Papp, H. Bachelez, A. Blauvelt, K.L. Winthrop, R. Romiti, M. Ohtsuki, N. Acharya, D.K. Braun, L. Mallbris, F. Zhao, W. Xu, C.D. Walls, B. Strober Tags: Clinical Trial Source Type: research